Marked reduction in serum uric acid levels after empagliflozin initiation in a patient with heart failure

This publication has 8 references indexed in Scilit:

• Serum uric acid lowering and effects of sodium‐glucose cotransporter‐2 inhibitors on gout: A meta‐analysis and meta‐regression of randomized controlled trials
  Diabetes, Obesity and Metabolism, 2023
• Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials
  Therapeutic Advances in Chronic Disease, 2022
• Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
  New England Journal of Medicine, 2020
• Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
  New England Journal of Medicine, 2019
• SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1
  American Journal of Physiology-Renal Physiology, 2019
• Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
  Diabetes, Obesity and Metabolism, 2018
• Effects of sodium‐glucose co‐transporter 2 ( SGLT2 ) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials
  Diabetes, Obesity and Metabolism, 2017
• SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
  Biopharmaceutics & Drug Disposition, 2014